MCID: CLR017
MIFTS: 44

Clear Cell Sarcoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Clear Cell Sarcoma

MalaCards integrated aliases for Clear Cell Sarcoma:

Name: Clear Cell Sarcoma 12 15 17
Sarcoma, Clear Cell 43 71
Adult Soft Part Clear Cell Sarcoma 12
Malignant Melanoma of Soft Tissues 12
Melanoma, Malignant, of Soft Parts 12
Clear Cell Sarcoma of Soft Parts 12
Malignant Melanoma of Soft Parts 12
Sarcoma Clear Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4233
MeSH 43 D018227
NCIt 49 C27370 C3745
SNOMED-CT 67 12622007
UMLS 71 C0206651 C1332198

Summaries for Clear Cell Sarcoma

Disease Ontology : 12 A sarcoma that is characterized by solid nests and fascicles of tumor cells with clear cytoplasm and prominent nucleoli. It presents as a slow growing mass that especially affects tendons and aponeuroses and it is deeply situated.

MalaCards based summary : Clear Cell Sarcoma, also known as sarcoma, clear cell, is related to melanoma of soft tissue and kidney clear cell sarcoma. An important gene associated with Clear Cell Sarcoma is ATF1 (Activating Transcription Factor 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and lung, and related phenotypes are cellular and integument

Wikipedia : 74 Clear-cell sarcoma is a rare form of cancer called sarcoma. It is known to occur mainly in the soft... more...

Related Diseases for Clear Cell Sarcoma

Diseases in the Small Cell Sarcoma family:

Clear Cell Sarcoma

Diseases related to Clear Cell Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 337)
# Related Disease Score Top Affiliating Genes
1 melanoma of soft tissue 33.9 EWSR1 CREB1 ATF1
2 kidney clear cell sarcoma 33.6 YWHAE WT1 NUTM2B EWSR1 ENO2 CCNB3
3 wilms tumor 1 32.0 WT1 SYP KIT IGF2 EWSR1 ENO2
4 rare tumor 31.6 KIT EWSR1
5 kidney rhabdoid cancer 30.9 EWSR1 ENO2
6 kidney sarcoma 30.6 YWHAE WT1 NUTM2B CCNB3 BCOR
7 rhabdoid tumor predisposition syndrome 1 30.6 WT1 SYP IGF2
8 sarcomatosis 30.6 WT1 EWSR1 ATF1
9 rhabdoid cancer 30.6 WT1 SYP EWSR1 ENO2
10 mesenchymal cell neoplasm 30.6 MLANA KIT EWSR1
11 paraganglioma 30.5 SYP S100B KIT ENO2
12 myxoid liposarcoma 30.5 FUS EWSR1 ATF1
13 epithelioid cell melanoma 30.5 MLANA MITF
14 myxoid chondrosarcoma 30.4 SYP S100B EWSR1
15 alveolar soft part sarcoma 30.4 TFE3 SYP ENO2
16 congenital mesoblastic nephroma 30.4 YWHAE WT1 KIT IGF2
17 epithelioid malignant peripheral nerve sheath tumor 30.3 SOX10 S100B MLANA
18 dermatofibrosarcoma protuberans 30.2 S100B KIT ENO2
19 sarcoma 30.2 WT1 TFE3 S100B KIT FUS EWSR1
20 neurilemmoma 30.2 SOX10 S100B MITF KIT ENO2
21 amelanotic melanoma 30.2 S100B MLANA MITF KIT
22 tuberous sclerosis 30.1 SYP S100B MLANA ENO2
23 neuroblastoma 30.1 SYP KIT IGF2 EWSR1 ENO2 CREB1
24 malignant spindle cell melanoma 30.0 SOX10 MLANA MITF KIT
25 small cell carcinoma 30.0 WT1 SYP KIT ENO2
26 extraosseous chondrosarcoma 29.9 SYP FUS EWSR1 ENO2
27 rhabdomyosarcoma 29.8 SYP S100B KIT IGF2 EWSR1 ENO2
28 leiomyosarcoma 29.8 WT1 S100B MLANA KIT IGF2 ENO2
29 malignant peripheral nerve sheath tumor 29.7 WT1 SOX10 S100B MLANA MITF KIT
30 microphthalmia 29.6 TFE3 SOX10 S100B MLANA MITF KIT
31 gastrointestinal stromal tumor 29.6 WT1 SYP S100B KIT IGF2 ENO2
32 perivascular epithelioid cell tumor 29.4 TFE3 SYP S100B MLANA MITF KIT
33 fibrous histiocytoma 29.2 S100B MITF FUS EWSR1 ENO2 CREB1
34 endometrial stromal sarcoma 29.2 YWHAE S100B NUTM2B KIT EWSR1 CCNB3
35 histiocytoma 29.1 MITF KIT FUS EWSR1 ENO2 CREB1
36 sarcoma, synovial 29.1 WT1 S100B KIT IGF2 FUS EWSR1
37 renal cell carcinoma, nonpapillary 29.1 WT1 TFE3 MITF KIT ERBB3 ENO2
38 ewing sarcoma 28.6 WT1 SYP S100B KIT IGF2 FUS
39 chondrosarcoma, extraskeletal myxoid 28.4 WT1 TFE3 SYP KIT FUS EWSR1
40 spindle cell sarcoma 11.1
41 wilms tumor 5 10.7
42 soft tissue sarcoma 10.7
43 melanoma 10.6
44 intracranial cysts 10.6 S100B ENO2
45 bednar tumor 10.6 S100B ENO2
46 melanoma in congenital melanocytic nevus 10.6 S100B MLANA
47 penis sarcoma 10.6 MLANA ENO2
48 reticular perineurioma 10.6 S100B KIT
49 primary hepatic neuroendocrine carcinoma 10.6 SYP S100B
50 malignant melanocytic neoplasm of the peripheral nerve sheath 10.6 SYP ENO2

Graphical network of the top 20 diseases related to Clear Cell Sarcoma:



Diseases related to Clear Cell Sarcoma

Symptoms & Phenotypes for Clear Cell Sarcoma

MGI Mouse Phenotypes related to Clear Cell Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 BCOR CCNB3 CREB1 ENO2 ERBB3 IGF2
2 integument MP:0010771 9.81 ERBB3 IGF2 KIT MITF MLANA S100B
3 normal MP:0002873 9.61 CREB1 ERBB3 KIT MITF S100B SOX10
4 pigmentation MP:0001186 9.17 ERBB3 KIT MITF MLANA SOX10 TFE3

Drugs & Therapeutics for Clear Cell Sarcoma

Drugs for Clear Cell Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Lenograstim Approved, Investigational Phase 3 135968-09-1
6
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
7
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
8
Sulfamethoxazole Approved Phase 3 723-46-6 5329
9
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Histamine Approved, Investigational Phase 3 51-45-6 774
12
Cyproheptadine Approved Phase 3 129-03-3 2913
13 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
14 Antibiotics, Antitubercular Phase 2, Phase 3
15 Anti-Bacterial Agents Phase 2, Phase 3
16
Liposomal doxorubicin Phase 3 31703
17 Antirheumatic Agents Phase 3
18 Cola Phase 3
19 Liver Extracts Phase 3
20 Adjuvants, Immunologic Phase 3
21 Analgesics Phase 3
22 Narcotics Phase 3
23 Anesthetics Phase 3
24 Anesthetics, General Phase 3
25 Analgesics, Opioid Phase 3
26 Adjuvants, Anesthesia Phase 3
27 Central Nervous System Depressants Phase 3
28 Anesthetics, Intravenous Phase 3
29 Gastrointestinal Agents Phase 3
30 Neurotransmitter Agents Phase 3
31 Dermatologic Agents Phase 3
32 Antipruritics Phase 3
33 Histamine H1 Antagonists Phase 3
34 Serotonin Agents Phase 3
35 Histamine Antagonists Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37 Serotonin Antagonists Phase 3
38 Anti-Allergic Agents Phase 3
39
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
40
Melphalan Approved Phase 2 148-82-3 4053 460612
41
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
42
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
43
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
44
Mecasermin Approved, Investigational Phase 2 68562-41-4
45
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
46
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
47
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
48
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
49
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
50
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
2 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
3 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
4 NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
5 National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
6 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK) Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
9 A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors Completed NCT00557609 Phase 2 ARQ 197
10 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
11 Treatment of High Risk Renal Tumors: A Groupwide Phase II Study Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
12 A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
13 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
14 A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas. Completed NCT00642941 Phase 2 RG1507
15 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
16 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study Completed NCT01136499 Phase 2 LBH589 (Panobinostat®)
17 A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion Recruiting NCT03132155 Phase 2 AMG 337
18 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
19 Preoperative Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Recruiting NCT03989596 Phase 2
20 Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer Recruiting NCT03241745 Phase 2 Nivolumab
21 Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE") Active, not recruiting NCT01524926 Phase 2 Crizotinib (PF-02341066)
22 Phase 2 Study With COmbination of Vemurafenib With Cobimetinib in B-RAF V600E/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab therapY Active, not recruiting NCT02968303 Phase 2 Vemurafenib and Cobimetinib
23 A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features Active, not recruiting NCT01164228 Phase 2 gemcitabine hydrochloride;sunitinib malate
24 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
25 Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma Completed NCT01061411 Phase 1 Dalteparin;Sunitinib Malate
26 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
27 Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT03618381 Phase 1
28 A Phase 1 Study Using Simvastatin in Combination With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
29 A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients Active, not recruiting NCT00258687 Phase 1
30 Sirolimus in Combination With Metronomic Therapy in Children With Recurrent and Refractory Solid Tumors: A Phase I Study Active, not recruiting NCT01331135 Phase 1 sirolimus
31 A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Cancer in East Anglia, Trent and West Midlands Unknown status NCT00757614
32 Descriptive Study to Evaluate the Information and Psychosocial Issues on the Risk on Infertility in Cancer Patients After Receiving Treatment in a Comprehensive Cancer Center Unknown status NCT01295463
33 Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Renal Tumor Project: Application of Array-Based Methods and Next Generation Sequencing to Identify Candidate Molecular Targets for High-Risk Wilms Tumors Completed NCT01118078
34 Improving Palliative Care for Patients With Cancer Completed NCT00253383
35 E-MOSAIC: A Multicenter Randomized Controlled Phase III Study of Longitudinal Electronic Monitoring of Symptoms and Syndromes Associated With Advanced Cancer in Patients Receiving Anticancer Treatment in Palliative Intention Completed NCT00477919
36 Pilot Study of Pencil Beam Scanning Proton Beam Radiation Therapy in Patients With Renal Tumors Recruiting NCT03810651 Early Phase 1
37 Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers Active, not recruiting NCT02162732
38 Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group Not yet recruiting NCT03967834
39 Renal Tumors Classification, Biology, and Banking Study Suspended NCT00898365
40 Focal Adhesion Kinase Expression in Pediatric Renal Tumors Withdrawn NCT01642095
41 Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors Withdrawn NCT00499291 paclitaxel albumin-stabilized nanoparticle formulation

Search NIH Clinical Center for Clear Cell Sarcoma

Cochrane evidence based reviews: sarcoma, clear cell

Genetic Tests for Clear Cell Sarcoma

Anatomical Context for Clear Cell Sarcoma

MalaCards organs/tissues related to Clear Cell Sarcoma:

40
Kidney, Bone, Lung, Skin, Liver, Lymph Node, Small Intestine

Publications for Clear Cell Sarcoma

Articles related to Clear Cell Sarcoma:

(show top 50) (show all 975)
# Title Authors PMID Year
1
The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells. 54 61
20362353 2010
2
Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. 54 61
20087159 2010
3
Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). 54 61
19561568 2009
4
Clear cell sarcoma of the mediastinum. 54 61
19433300 2009
5
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. 54 61
18627530 2008
6
Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity. 54 61
17075294 2006
7
MITF: master regulator of melanocyte development and melanoma oncogene. 54 61
16899407 2006
8
EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation. 54 61
17000668 2006
9
Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. 54 61
16867224 2006
10
Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. 54 61
16766266 2006
11
Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. 54 61
16258500 2005
12
Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses). 54 61
15588860 2005
13
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. 54 61
15150091 2004
14
The melanocyte inducing factor MITF is stably expressed in cell lines from human clear cell sarcoma. 54 61
12966428 2003
15
Karyotypic divergence and convergence in two synchronous lung metastases of a clear cell sarcoma of tendons and aponeuroses with t(12;22)(q13;q12) and type 1 EWS/ATF1. 54 61
12935923 2003
16
Case report: case of clear cell sarcoma surviving with the primary lesion for 20 years after resection of a metastatic lymph node. 54 61
14666625 2003
17
Cytogenetic comparison between clear cell sarcoma and a case of acral clear cell melanoma. 54 61
16285301 2003
18
Minimal structural elements of an inhibitory anti-ATF1/CREB single-chain antibody fragment (scFv41.4). 54 61
12831531 2003
19
Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. 54 61
11865845 2002
20
Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics. 54 61
11145252 2001
21
Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: further evidence for melanocytic differentiation. 54 61
11211309 2001
22
Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11. 54 61
11063792 2000
23
Tumor cell viability in clear cell sarcoma requires DNA binding activity of the EWS/ATF1 fusion protein. 54 61
10574952 1999
24
New type of chimeric fusion product between the EWS and ATFI genes in clear cell sarcoma (malignant melanoma of soft parts). 54 61
9824209 1998
25
Insulin-like growth factor 2 gene imprinting in clear cell sarcoma of the kidney. 54 61
9385942 1997
26
The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator. 54 61
8552387 1996
27
The emerging molecular genetics of sarcoma translocations. 54 61
7493135 1995
28
Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. 54 61
8187063 1994
29
Clear cell sarcoma of the kidney expresses insulinlike growth factor-II but not WT1 transcripts. 54 61
8424465 1993
30
A Rare Case of Primary Dermal Clear Cell Sarcoma with Focal Epidermotropism: An Entity Difficult to Distinguish from Melanoma. 61
32012324 2020
31
An NRAS mutation in primary malignant melanoma of the lung: a case report. 61
32028967 2020
32
Primary clear cell sarcoma in the lung apex with spinal metastasis: a fatal outcome. 61
31924706 2020
33
Clear Cell Sarcoma of the Kidney. 61
30917048 2020
34
Clear cell sarcoma like tumor of gastrointestinal tract: Experience of three cases and review of literature. 61
32031130 2020
35
Compound Clear Cell Sarcoma of the Skin-A Potential Diagnostic Pitfall: Report of a Series of 4 New Cases and a Review of the Literature. 61
31688004 2020
36
Prognostic analysis of surgically treated clear cell sarcoma: an analysis of a rare tumor from a single center. 61
31243628 2019
37
BCOR-CCNB3 fusion-positive clear cell sarcoma of the kidney. 61
31876361 2019
38
Eribulin suppresses clear cell sarcoma growth by inhibiting cell proliferation and inducing melanocytic differentiation both directly and via vascular remodeling. 61
31796507 2019
39
Expanding the Phenotypic Spectrum of Mesenchymal Tumors Harboring the EWSR1-CREM Fusion. 61
31305268 2019
40
Diagnostic Utility of BCOR Antibody in Clear Cell Sarcomas of Kidney. 61
31875746 2019
41
Clear cell sarcoma of the kidney in a 62-year-old patient presenting with generalized pruritus. 61
31676003 2019
42
Is TLE1 Expression Limited to Synovial Sarcoma? Our Experience at Shifa International Hospital, Pakistan. 61
31893185 2019
43
A renal cell carcinoma with EWSR1-TFE3 fusion gene. 61
31774608 2019
44
Lessons learned from the developmental origins of childhood renal cancer. 61
31738020 2019
45
CRTC1-TRIM11 fusion defined melanocytic tumors: A series of four cases. 61
31237704 2019
46
[Clinicopathological study of clear cell sarcoma of the kidney]. 61
31594046 2019
47
Clear cell sarcoma of soft tissue in pleural cavity: A case report. 61
31624764 2019
48
Primary Gastrointestinal-Type Clear Cell Sarcoma-like Tumor of the Bronchus: A Hitherto Unreported Bronchial Tumor. 61
31445737 2019
49
Clear Cell Sarcoma-Like Tumor of the Gastrointestinal Tract. 61
29623567 2019
50
Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes. 61
31404317 2019

Variations for Clear Cell Sarcoma

Expression for Clear Cell Sarcoma

Search GEO for disease gene expression data for Clear Cell Sarcoma.

Pathways for Clear Cell Sarcoma

Pathways related to Clear Cell Sarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.37 WT1 TFE3 MITF FUS EWSR1 ATF1
2 11.33 SYP SOX10 S100B
3 10.88 MITF CREB1 ATF1
4 10.87 SOX10 MITF KIT CREB1

GO Terms for Clear Cell Sarcoma

Cellular components related to Clear Cell Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.36 WT1 TRIM11 TFE3 SOX10 S100B MITF

Biological processes related to Clear Cell Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.85 WT1 SOX10 MITF KIT FUS ATF1
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.8 WT1 TFE3 SOX10 MITF IGF2 CREB1
3 positive regulation of gene expression GO:0010628 9.72 WT1 SOX10 MITF KIT ERBB3
4 regulation of transcription, DNA-templated GO:0006355 9.61 WT1 TFE3 SOX10 MITF IGF2 FUS
5 regulation of osteoclast differentiation GO:0045670 9.4 TFE3 MITF
6 positive regulation of cardiac muscle tissue development GO:0055025 9.16 ERBB3 CREB1
7 melanocyte differentiation GO:0030318 8.8 SOX10 MITF KIT

Molecular functions related to Clear Cell Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 YWHAE WT1 TRIM11 TFE3 SOX10 S100B
2 DNA-binding transcription factor activity GO:0003700 9.8 WT1 TFE3 SOX10 MITF CREB1 ATF1
3 transcription regulatory region DNA binding GO:0044212 9.55 WT1 TFE3 SOX10 CREB1 BCOR
4 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.43 WT1 TFE3 SOX10 MITF CREB1 ATF1
5 identical protein binding GO:0042802 9.28 YWHAE SYP SOX10 S100B FUS EWSR1

Sources for Clear Cell Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....